Company news
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) news
Iovance Biotherapeutics, Inc. news releases on 6ix. Latest, Oct 1, 2026: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Press releases & updates
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
September 30, 2026
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
October 1, 2026
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
September 28, 2026
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
July 30, 2026
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 3, 2026
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
June 1, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - May 22, 2026
May 26, 2026
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
May 7, 2026
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
April 27, 2026
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
February 23, 2026
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
February 23, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
February 23, 2026
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
February 11, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
February 5, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 16, 2026
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
November 6, 2025
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
November 3, 2025
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
October 23, 2025
Iovance Biotherapeutics to Present at Upcoming Conferences
August 29, 2025
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
August 18, 2025
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
August 7, 2025
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
July 24, 2025
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
July 15, 2025
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
July 14, 2025
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
July 10, 2025
Iovance Biotherapeutics to Present at Upcoming Conference
June 10, 2025
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
June 2, 2025
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
May 22, 2025
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
May 8, 2025
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
May 2, 2025
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
April 23, 2025
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
February 27, 2025
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
February 18, 2025
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
February 9, 2025
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
November 25, 2024
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
November 6, 2024
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
August 7, 2024
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
June 27, 2024
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
May 22, 2024
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
May 8, 2024
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
March 3, 2024
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
February 27, 2024
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
February 19, 2024
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
February 15, 2024
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
December 26, 2023
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
November 6, 2023
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
October 30, 2023
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
October 15, 2023
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
August 7, 2023
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
July 12, 2023